Table 2

Demographic, clinical and biological characteristics of pSS patients according to ancestry in sub-group populations

Caucasian vs sub-SaharanCaucasian vs Afro-Caribbean
Caucasian, N=148*Sub-Saharan, N=43*P value†Afro-Caribbean, N=31*P value†
Follow-up duration6.0 (2.0, 11.0)5.0 (2.5, 11.0)>0.96.0 (2.0, 11.5)0.9
 Age at symptoms onset52.0 (37.8, 59.2)35.5 (25.5, 44.0)<0.00144.5 (36.5, 51.0)0.047
 Age at Sjögren’s diagnosis56.0 (44.8, 64.0)40.0 (31.0, 48.0)<0.00147.0 (36.5, 53.5)<0.001
 Sex, Female139/148 (94%)39/43 (91%)0.529/31 (94%)>0.9
 Fatigue72/138 (52%)26/31 (84%)0.00117/21 (81%)0.013
 Oral dryness133/148 (90%)33/43 (77%)0.02528/31 (90%)>0.9
 Eye dryness127/148 (86%)31/43 (72%)0.03622/31 (71%)0.044
 Shiermer abnormal74/108 (69%)16/28 (57%)0.313/18 (72%)0.8
 Low salivary flux37/95 (39%)7/27 (26%)0.25/14 (36%)0.8
Chisholm score 3–496/123 (78%)34/40 (85%)21/26 (81%)0.8
 Lymphoma6/148 (4.1%)3/43 (7.0%)0.43/31 (9.7%)0.2
 Gammaglobulins titre (g/L)13.4 (9.9, 16.9)19.6 (14.7, 24.2)<0.00117.6 (15.0, 21.0)<0.001
 β2-microglobulintitre (mg/L)2.2 (1.8, 2.9)2.3 (2.0, 2.7)>0.92.2 (1.9, 2.7)0.8
 Rheumatoid Factor79/148 (53%)17/43 (40%)0.1113/31 (42%)0.2
 anti-SSA106/148 (72%)38/43 (88%)0.02527/31 (87%)0.073
 anti-SSB58/148 (39%)20/43 (47%)0.48/31 (26%)0.2
 anti-DNA4/148 (2.7%)0/43 (0%)0.61/31 (3.2%)>0.9
 anti-SM0/148 (0%)1/43 (2.3%)0.20/31 (0%)
 anti-RNP4/148 (2.7%)7/43 (16%)0.0031/31 (3.2%)>0.9
 Cryoglobulinaemia26/148 (18%)8/43 (19%)0.97/31 (23%)0.5
 Low C36/148 (4.1%)0/43 (0%)0.30/31 (0%)0.6
 Low C435/148 (24%)9/43 (21%)0.75/31 (16%)0.4
 cumClinESSDAI4.5 (2.0, 9.0)9.0 (4.0, 18.0)0.0026.0 (2.0, 12.0)0.5
 Steroid prescription48/148 (32%)19/43 (44%)0.24/31 (13%)0.029
 Immunosuppressors31/148 (21%)16/43 (37%)0.0294/31 (13%)0.3
  • *n/N (%); median (IQR).

  • †Pearson’s χ2 test; Wilcoxon rank sum test; Fisher’s exact test.

  • CNS, central nervous system; ESSDAI, EULAR Sjögren’s Syndrome Disease Activity Index; PNS, peripheral nervous system; pSS, primary Sjögren’s syndrome.